CEO Paul Laviolette Buys $295K in Shares Through Company's ATM Program
PLSE sits 59% above its 52-week low of $12.56 on elevated volume (3.1× avg).
Summary
Pulse Biosciences CEO Paul Laviolette bought $295,350 worth of company stock through its ATM program, demonstrating strong confidence following recent positive clinical developments.
Key Events · Ownership and Investor Activity · PLSE
-
CEO Open Market Purchase
CEO Paul A. Laviolette acquired 15,000 shares of common stock for $295,350 at a price of $19.69 per share.
-
Purchase via ATM Program
The shares were acquired through the company's existing at-the-market (ATM) equity offering program, following a recent board approval for affiliates to purchase shares, as noted in an 8-K filing on May 6, 2026.
-
Executive Confidence Signal
This purchase by the CEO, especially through the ATM program, indicates strong executive confidence in the company's future, building on recent positive clinical data and regulatory advancements.
Analysis · PLSE · Industrial Applications And Services
Pulse Biosciences' CEO, Paul Laviolette, purchased shares directly from the company's at-the-market (ATM) equity offering program. This transaction follows a recent board approval for affiliates to buy shares through the ATM, and it signals strong executive confidence in the company's prospects, especially after a series of positive clinical data announcements.
At the time of this filing, PLSE was trading at $20.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.